Assembly Biosciences Inc. Registered Shares o.N.
- BID
23
- ASK
23.1
- 435 Units433 Units
- 07/21, 20:11:47 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
43.18%
Market Cap
-
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-0.48 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 22.95 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 08:01:49 PM | |
| DAILY VOLUME (UNITS) | 160 | |
| DAILY HIGH / LOW | 22.95 | 21.5 |
| PREV. DAY'S PRICE | 22.05 | (07/20) |
| CHANGE DAY BEFORE | +0.90 | 4.08 % |
| 52 WEEK HIGH / LOW | 33.8 (12/01) | 14.55 (08/01) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -12.37 | -6.19 | -0.48 | -2.26 | -3.37 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | - | - |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | - |
PRICE - BOOK RATIO | 1.31 | 3.53 | 2.61 | - | - |
PRICE - SALES RATIO | 6.29 | 3.32 | 5.27 | - | - |
PRICE - CASH FLOW RATIO | 1.98 | - | - | - | - |
Master Data
| WKN | A402CB |
| ISIN | US0453962070 |
| SYMBOL | V7B |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | ASSEMBLY BIOSCIENCES INC |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -6.77 % | 5.50 % | -7.16 % | -4.13 % | 43.18 % | 94.65 % | -37.50 % | -18.93 % |
| HIGH | 23.95 | 26.10 | 26.95 | 26.95 | 33.80 | 129.46 | 129.46 | 28.80 |
| LOW | 22.05 | 20.95 | 18.88 | 18.88 | 14.55 | 6.89 | 6.89 | 18.88 |
Dividende
pro Aktie
ASSEMBLY BIOSCIENCES INC does not deliver dividend information
Company profile
Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. Its lead programs, ABI-5366 and ABI-1179, long-acting helicase-primase inhibitors, are in clinical development for recurrent genital herpes. The company is partnered with Gilead Sciences to advance current and future antiviral programs across herpesviruses, HBV, and HDV. Assembly Biosciences was founded in 2005 and is headquartered in South San Francisco, CA.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.